← Back to Search

Pulmozyme for Coronavirus Disease

Phase 2
Waitlist Available
Research Sponsored by Boston Children's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days

Summary

This trial is designed to study whether the use of Pulmozyme can improve clinical outcomes in patients with severe COVID-19 pneumonia who require mechanical ventilation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Ventilator-free days at 28 days
Secondary study objectives
change in airway resistance
change in lung compliance
length of stay (ICU and hospital)
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Study DrugExperimental Treatment1 Intervention
Study drug
Group II: PlaceboPlacebo Group1 Intervention
Placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pulmozyme
2005
Completed Phase 4
~20

Find a Location

Who is running the clinical trial?

South Shore HospitalOTHER
12 Previous Clinical Trials
10,781 Total Patients Enrolled
Boston Children's HospitalLead Sponsor
783 Previous Clinical Trials
5,581,221 Total Patients Enrolled
Brigham and Women's HospitalOTHER
1,664 Previous Clinical Trials
11,834,926 Total Patients Enrolled
~11 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top